Send me real-time posts from this site at my email

Maxim Group Thinks MTBC’s Stock is Going to Recover

In a report released yesterday, Allen Klee from Maxim Group reiterated a Buy rating on MTBC (MTBCResearch Report), with a price target of $20.00. The company's shares closed last Monday at $8.00, close to its 52-week low of $7.29.

According to, Klee has 0 stars on 0-5 stars ranking scale with an average return of -9.9% and a 31.6% success rate. Klee covers the Technology sector, focusing on stocks such as Digital Turbine, Mitek Systems, and Biotricity.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MTBC with a $18.00 average price target.

See today’s analyst top recommended stocks >> The company has a one-year high of $12.84 and a one-year low of $7.29. Currently, MTBC has an average volume of 84.79K. Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MTBC in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. MTBC, Inc. is a healthcare information technology company, which engages in the provision of web-based solutions and business services to healthcare providers. It operates through the Healthcare Information Technology (IT) and Practice Management segments. The Healthcare IT segment includes revenue cycle management and other services. The Practice management segment involves in the management of three medical practices. The company was founded by Mahmud Ul Haq on September 28, 2001 and is headquartered in Somerset, NJ. Read More on MTBC:

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue